ACHN_30%20May%202013(2)

Recommendations

Info

NS5B Polymerase Inhibitor ACH-3422 8
ACH-3422 NS5B Polymerase Nucleotide Inhibitor • ACH-3422 is a nucleotide prodrug of uridine analog • Virology – Specific for HCV polymerase – Highly potent (EC 50 : GT 1a 65nM, GT 1b 50 nM, GT 2a 85 nM) – Highly specific for HCV – Pan-genotypic activity with a high barrier to resistance • PK and Metabolism – Rapid conversion of prodrug to monophosphate in microsomes and in hepatocytes – PK profiles suggests once-daily (QD) dosing • Safety – 14-day animal tox completed – High exposure of triphosphate in liver – No significant findings at the highest dose tested 9
Page 1 and 2: Achillion Pipeline Update May 30, 2
Page 3 and 4: Experienced Management Team Milind
Page 5 and 6: HCV Therapeutics: Target Profiles S
Page 7: Sovaprevir + ACH-3102 +/- RBV Phase
Page 11 and 12: ACH-3422 Preclinical Profile • Ra
Page 13 and 14: Capitalization and Liquidity Balanc
Page 15: Achillion Pharmaceuticals, Inc. NAS

ACHN_30%20May%202013(2)

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?